Kumatakenin 是一种具有口服活性的凋亡 (apoptosis) 诱导剂和自噬 (autophagy) 抑制剂,其与小鼠 ATG5 的 Kd 为 2.94 μM,可通过提高 caspase-3、caspase-8 和 caspase-9 活性在卵巢癌细胞中诱导 caspase 依赖性凋亡,并在卵巢癌细胞中降低趋化因子、促癌因子的表达及抑制 M2 型巨噬细胞极化,同时通过使 TRIM65 功能失活、降低 FASN 的表达及稳定性来抑制食管癌细胞的增殖、迁移、侵袭及肿瘤进展,通过与 ATG5 相互作用降低其蛋白水平、减少 LC3 水平并减少海马体自噬体的数量,通过与 Eno3 结合上调其表达、降低 IRP1 mRNA 的稳定性及表达水平来抑制铁死亡 (ferroptosis)、减轻肠道炎症并恢复上皮屏障功能,还可增强抗生素对致病菌的作用效果、抑制 SARS-CoV-2 复制并减少细胞因子的产生,可用于卵巢癌、食管癌、抑郁症、结肠炎的相关研究。
产品编号: MS-P85778 纯度: 99.31% CAS No.: 3301-49-3 分子式: C17H14O6 分子量: 314.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价

产品描述

Kumatakenin 是一种具有口服活性的凋亡 (apoptosis) 诱导剂和自噬 (autophagy) 抑制剂,其与小鼠 ATG5 的 Kd 为 2.94 μM,可通过提高 caspase-3、caspase-8 和 caspase-9 活性在卵巢癌细胞中诱导 caspase 依赖性凋亡,并在卵巢癌细胞中降低趋化因子、促癌因子的表达及抑制 M2 型巨噬细胞极化,同时通过使 TRIM65 功能失活、降低 FASN 的表达及稳定性来抑制食管癌细胞的增殖、迁移、侵袭及肿瘤进展,通过与 ATG5 相互作用降低其蛋白水平、减少 LC3 水平并减少海马体自噬体的数量,通过与 Eno3 结合上调其表达、降低 IRP1 mRNA 的稳定性及表达水平来抑制铁死亡 (ferroptosis)、减轻肠道炎症并恢复上皮屏障功能,还可增强抗生素对致病菌的作用效果、抑制 SARS-CoV-2 复制并减少细胞因子的产生,可用于卵巢癌、食管癌、抑郁症、结肠炎的相关研究。

生物实验数据

生物活性 Kumatakenin is an orally active apoptosis inducer and autophagy inhibitor with a Kd of 2.94 μM for mouse ATG5 that induces caspase-dependent apoptosis in ovarian cancer cells by increasing caspase-3, caspase-8, and caspase-9 activities, reduces the expression of chemokines and oncogenic factors and inhibits M2 macrophage polarization in ovarian cancer cells, inhibits the proliferation, migration, invasion, and tumor progression of esophageal cancer cells by inactivating TRIM65 and decreasing the expression and stability of FASN, interacts with ATG5 to reduce its protein levels, decrease LC3 levels, and reduce the number of autophagosomes in the hippocampus, binds to Eno3 to upregulate its expression, decreases the stability and expression levels of IRP1 mRNA, inhibits ferroptosis, alleviates intestinal inflammation, and restores epithelial barrier function, enhances the effects of antibiotics against pathogenic bacteria, inhibits SARS-CoV-2 replication, and reduces cytokine production, and can be used for research related to ovarian cancer, esophageal cancer, depression, and colitis.
体外研究
(In Vitro)

Kumatakenin (0-100 μM; 48 h) 可在人源 A2780 和 SKOV3 卵巢癌细胞中诱导呈剂量依赖性的细胞生长抑制。
Kumatakenin (0-30 μM; 48 h) 可增加人 SKOV3 卵巢癌细胞中提示细胞死亡的亚 G1 期细胞比例,且不会诱导细胞周期阻滞,诱导由 caspase-3 激活介导的凋亡性细胞死亡,诱导 caspase-3、caspase-8 和 caspase-9 呈剂量依赖性激活。
Kumatakenin (0-30 μM; 24 h) 可呈剂量依赖性下调人 SKOV3 卵巢癌细胞中 MCP-1 和 RANTES 的 mRNA 表达和分泌。
Kumatakenin (0-40 μM; 24 h) 可呈剂量依赖性降低 THP-1 来源肿瘤相关巨噬细胞 (TAMs) 中 M2 型巨噬细胞标志物 CD206 和 Trem-2 的 mRNA 和蛋白表达,降低促肿瘤因子 IL-10、VEGF、MMP-2 和 MMP-9 的 mRNA 表达,降低 MMP-2 和 MMP-9 的蛋白表达水平,减少 IL-10 和 VEGF 的分泌。
Kumatakenin (0-40 μM; 12 h) 可呈剂量依赖性降低 KYSE410、TE-1、TE-10 和 Case17 食管癌细胞中 TRIM65 与 FASN 的 mRNA 表达水平。
Kumatakenin (0-40 μM; 12 h) 可抑制 KYSE410、TE-1、TE-10 和 Case17 食管癌细胞中 TRIM65 与 FASN 的共表达。
Kumatakenin (0-40 μM; 12 h) 可在处理 12 h 后,以剂量依赖的方式降低 KYSE410、TE-1、TE-10 和 Case17 食管癌细胞的迁移、侵袭能力及促 EMT 标志物的表达,同时上调抗 EMT 标志物的表达。
Kumatakenin (0-40 μM; 24 h) 可在共处理 24 h 后,以剂量依赖的方式减少 Palmitic acid (PA) (MS-A29753) 和 Oleic acid (OA) (MS-M89265) 诱导的 KYSE410 及 TE-1 食管癌细胞内甘油三酯的积累,降低细胞中的脂质沉积及 TRIM65 表达。
Kumatakenin (40 μM; 24 h) 可降低 KYSE410 和 TE-1 食管癌细胞中由葡萄糖从头合成棕榈酸的水平。
Kumatakenin (40 μM) 可在重构了 TRIM65 的 KYSE410 和 TE-1 食管癌细胞中抑制 TRIM65 介导的 FASN 的 K63 连接型多聚泛素化修饰。
Kumatakenin (40-80 μM) 可降低经 PA 处理、重构 TRIM65 的 KYSE410 和 TE-1 食管癌细胞中 TRIM65 介导的 FASN 的 K63 位连接多聚泛素化修饰。
Kumatakenin (6.25-100 μM) 可与纯化的 ATG5 蛋白结合,其 Kd 为 2.94×10-6 M。
Kumatakenin (1-20 μM) 可逆转 Corticosterone (CORT) (MS-F46715) 诱导的 HT-22 细胞活力丧失,并调控 HT-22 细胞中自噬相关蛋白的表达水平 (上调 P62,下调 ATG5 和 LC3),但上述作用会被 ATG5 过表达所消除。
Kumatakenin (10-80 μM; 48 h) 可提高经 Erastin (MS-C46386) 处理的 MODE-K 小鼠结肠上皮细胞的存活率,降低细胞中脂质 ROS 水平,以 Eno3 依赖的方式降低细胞内铁水平、 IRP1 蛋白水平升高,提高细胞中 IRP1 mRNA 的降解速率。

Cell Viability Assay

Cell Line: human A2780 ovarian cancer cells, human SKOV3 ovarian cancer cells
Concentration: 0, 1.563, 3.125, 6.25, 12.5, 25, 50, 100 μM
Incubation Time: 48 h
Result: Induced dose-dependent cell growth inhibition in both A2780 and SKOV3 cells, with increasing inhibition observed at higher concentrations.

Cell Cycle Analysis

Cell Line: human SKOV3 ovarian cancer cells
Concentration: 0, 5, 15, 30 μM
Incubation Time: 48 h
Result: Increased the percentage of cells in the sub-G1 phase from 2.33% (untreated) to 6.52% (5 μM), 8.58% (15 μM), and 21.06% (30 μM).
Did not induce significant cell cycle arrest in other phases.

Apoptosis Analysis

Cell Line: human SKOV3 ovarian cancer cells
Concentration: 30 μM
Incubation Time: 0, 12, 24, 48 h
Result: Increased the total apoptotic cell population from 1.47% (0 h) to 11.14% (12 h), 23.01% (24 h), and 62.19% (48 h).

Western Blot Analysis

Cell Line: human SKOV3 ovarian cancer cells
Concentration: 0, 5, 15, 30 μM
Incubation Time: 48 h
Result: Induced dose-dependent increases in cleaved caspase-3, cleaved caspase-8, and cleaved caspase-9, with fold changes (normalized to β-actin) ranging from 1 to >3 for all three caspases at increasing concentrations.

Real Time qPCR

Cell Line: human SKOV3 ovarian cancer cells
Concentration: 0, 5, 15, 30 μM
Incubation Time: 24 h
Result: Reduced MCP-1 mRNA expression to ~90% (5 μM), ~75% (15 μM), and ~55% (30 μM) of control levels.
Reduced RANTES mRNA expression to ~90% (5 μM), ~65% (15 μM), and ~55% (30 μM) of control levels.

ELISA Assay

Cell Line: human SKOV3 ovarian cancer cells
Concentration: 30 μM
Incubation Time: 24 h
Result: Reduced MCP-1 secretion to ~60% of control levels.
Reduced RANTES secretion to ~70% of control levels.

Real Time qPCR

Cell Line: THP-1-derived tumour-associated macrophages (TAMs)
Concentration: 0, 10, 20, 40 μM
Incubation Time: 24 h
Result: Reduced CD206 mRNA expression to ~95% (10 μM), ~75% (20 μM), and ~65% of TAM control levels.
Reduced Trem-2 mRNA expression to ~95% (10 μM), ~85% (20 μM), and ~75% of TAM control levels.\nReduced IL-10 mRNA expression to ~95% (10 μM), ~35% (20 μM), and ~25% of TAM control levels.
Reduced VEGF mRNA expression to ~90% (10 μM), ~45% (20 μM), and ~35% of TAM control levels.
Reduced MMP-2 mRNA expression to ~95% (10 μM), ~30% (20 μM), and ~20% of TAM control levels.
Reduced MMP-9 mRNA expression to ~95% (10 μM), ~60% (20 μM), and ~50% of TAM control levels.

Western Blot Analysis

Cell Line: THP-1-derived tumour-associated macrophages (TAMs)
Concentration: 30 μM
Incubation Time: 24 h
Result: Reduced CD206 protein expression to ~40% of TAM control levels.
Reduced Trem-2 protein expression to ~60% of TAM control levels.\nReduced MMP-2 and MMP-9 protein expression compared to TAM control levels.

ELISA Assay

Cell Line: THP-1-derived tumour-associated macrophages (TAMs)
Concentration: 40 μM
Incubation Time: 24 h
Result: Reduced IL-10 secretion to ~65% of TAM control levels.
Reduced VEGF secretion to ~45% of TAM control levels.

Real Time qPCR

Cell Line: KYSE410, TE-1, TE-10, Case17
Concentration: 0 μM, 10 μM, 20 μM, 40 μM
Incubation Time: 12 h
Result: Caused a dose-dependent reduction in TRIM65 mRNA expression in all four cell lines.
Caused a dose-dependent reduction in FASN mRNA expression in all four cell lines.

Immunofluorescence

Cell Line: KYSE410, TE-1, TE-10, Case17
Concentration: 40 μM
Incubation Time: 12 h
Result: Inhibited the co-expression of TRIM65 and FASN in all four cell lines.

Cell Migration Assay

...(内容过长已截断)
Cell Line: KYSE410, TE-10, TE-1, Case17
Concentration: 0 μM, 10 μM, 20 μM, 40 μM
Incubation Time:
体内研究
(In Vivo)

Kumatakenin (p.o.;每日 1 次;持续 22 天;80 mg/kg) 可显著降低雄性 Balb/c 裸鼠食管异种移植瘤的体积与重量。
Kumatakenin (0.56-2.25 mg/kg) 可通过降低血浆 CORT 水平、升高血浆 5-HT、DA 及 BDNF 水平,下调 ATG5 与 LC3 表达以抑制海马区过度自噬,同时恢复海马神经元结构与 BDNF 水平,缓解 CORT 诱导的雄性 C57BL/6J 小鼠抑郁样行为。
Kumatakenin (25-100 mg/kg;灌胃;每日一次;连续 9 天) 可通过上调 Eno3 并调控 Eno3-IRP1 轴以降低细胞铁水平、抑制结肠上皮细胞铁死亡,从而显著缓解 DSS (MS-A45736) 诱导的雄性 C57BL/6 小鼠结肠炎。

Animal Model: Balb/c nude (male, 4 weeks old, 18-20 g, subcutaneously injected with 1×107 KYSE410 esophageal cancer cells/1×107 TE-1 esophageal cancer cells/1×107 TRIM65-overexpressing AdTRIM65 KYSE410 esophageal cancer cells)
Dosage: 80 mg/kg
Administration: p.o.; daily; 22 days
Result: Reduced tumor volume over the 22-day observation period (final mean tumor volume was lower than controls).
Reduced final tumor weight.
Animal Model: C57BL/6 (male, 28-35 g, DSS-induced colitis)
Dosage: 25 mg/kg; 100 mg/kg
Administration: i.g.; daily; 9 days
Result: Restored colonic mucosal bleeding, vascular patterns, intestinal villi atrophy, and reduced inflammatory cell infiltration.
Increased colon length, decreased Disease Activity Index score, alleviated diarrhea and rectal bleeding, and increased body weight and food intake.
Reduced colonic myeloperoxidase activity, and colonic levels of pro-inflammatory cytokines TNF-α and IL-6, and reduced serum fluorescein isothiocyanate-dextran levels, restoring epithelial barrier function.
Restored mitochondrial morphology in colonic epithelial cells, reduced colonic iron levels, decreased colonic malonaldehyde content, and reduced 4-hydroxynonenal expression in colonic tissues, suppressing ferroptosis.
Upregulated Eno3 protein expression in colonic tissues.
Reversed protective effects (improved colonoscopy findings, increased colon length, reduced Disease Activity Index, restored mitochondrial morphology, reduced colonic iron levels) when Eno3 was inhibited with ENOblock.
Reduced colonic IRP1 mRNA and protein expression, and promoted IRP1 mRNA degradation.
Blocked regulation of IRP1 expression when Eno3 was inhibited.
性状 固体
颜色 Light yellow to green yellow

化学信息

分子量 314.29
分子式 C17H14O6
CAS No. 3301-49-3

储存&溶解度

储存方式

4°C, sealed storage, away from moisture and light

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (79.54 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.1818 mL15.9089 mL31.8177 mL79.5444 mL
5 mM0.6364 mL3.1818 mL6.3635 mL15.9089 mL
10 mM0.3182 mL1.5909 mL3.1818 mL7.9544 mL
15 mM0.2121 mL1.0606 mL2.1212 mL5.3030 mL
20 mM0.1591 mL0.7954 mL1.5909 mL3.9772 mL
25 mM0.1273 mL0.6364 mL1.2727 mL3.1818 mL
30 mM0.1061 mL0.5303 mL1.0606 mL2.6515 mL
40 mM0.0795 mL0.3977 mL0.7954 mL1.9886 mL
50 mM0.0636 mL0.3182 mL0.6364 mL1.5909 mL
60 mM0.0530 mL0.2651 mL0.5303 mL1.3257 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础

  • 客服

    2851296953

    18923798467

    微信洽谈